Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

PBYI

Phase 2

Alisertib

HER2-Negative Metastatic Breast Cancer

2025

ALISCA™-Breast1. 11/20/24- Initiated trial. Initial data in 2025.

Data readout

DWTX

Phase 2b

Halneuron

Chemotherapy-induced neuropathic pain (CINP)

H2 2025

HALT-CINP trial. 10/7/24 Business combination w/ Wex. FDA Fast Track designation. 1/21/25- Dose first patient in Q1 2025. Interim data in H2 2025. 3/18/25- First patient dosed in Ph2b.

Data readout

FNCH

Phase 1/2

CP101

Ulcerative colitis

2025

Collab w/ Brigham & Women’s Hospital. Data in 2025.

Data readout

INCY

Phase 1

INCA033989 (mCALR)

Myelofibrosis

2025

Ph1 study ongoing and enrolling. Q2 '24 Initial data in 2025.

Data readout

NBTX

Phase 1

NBTXR3 + Anti-PD-1

Head and Neck Recurrent and/or Metastatic (R/M HNSCC)

2025

Study 1100. 4/25/23-Established (RP2D). 5/21/24- Dose escalation part completed & dose expansion part ongoing. 6/2/24- Presented new data at ASCO '24. Provide first data from cohort 3 dose expansion part in 2025.

Data readout

IONS

Phase 3

Zilganersen (ION373)

Alexander Disease

H2 2025

7/18/24- Completed enrollment in pivotal trial. Topline data in H2 2025. 10/1/24- Granted FDA Fast Track designation.

Data readout

ALXO

Phase 1

Evorpacept (ALX148) + ENHERTU®

Breast cancer (HER2-positive and HER2-low breast cancer)

H2 2025

I-SPY-P1-TRIAL. 3/13/23- First patient dosed. W/ Quantum Leap Healthcare. Topline in H2 2025

Data readout

SONN

Phase 1

SON-1010 (IL12-FHAB) +/- Trabectedin

Advanced solid tumors

H2 2025

SB101 trial. 9/18/24- Completed enrollment and dosing in Ph1 trial. 12/09/24- Topline safety data reported. Seeking partnership opportunities to help support later stage development. 1/21/25- Trial expansion in combo w/ Trabectedin with topline data in H2 2025.

Data readout

ARWR

Phase 1/2

ARO-C3 (RNAi)

Complement mediated diseases, paroxysmal nocturnal hemoglobinuria (PNH), Renal disease, IgA Nephropathy, C3 Glomerulopathy (C3G)

2025

AROC3-1001 trial: 2/28/23- Encouraging interim results from Part 1. 3/10/25- Reported topline results from Part 2 in patients with IgA nephropathy. Share more Ph1/2 study data at upcoming medical meeting in 2025.

Additional Data readout

RCUS

Phase 2

Domvanalimab (FcR-silent TIGIT antibody)

metastatic gastric (G), gastroesophageal junction (GEJ) or esophageal (E) adenocarcinoma

2025

EDGE-Gastric trial. Encouraging new preliminary Ph2 data presented at ASCO 11/7/23. Updated PFS and ORR data at ASCO meeting on June 1, 2024. OS data to be presented in 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20